Fig. 3. PG16 protected SCID-hu Thy/Liv mice from infection with HIVJD in three independent challenge studies with progressively lower antibody dose ranges.
(A) Mean HIV RNA was reduced to <102.5 copies per 106 implant cells in mice treated i.p. with 50–500 µg PG16 three times per week beginning the day before inoculation and continuing until implant collection at 14 days. Similar reductions in HIV RNA were observed in mice treated i.p. with 500 µg PG9 under the same regimen as well as treatment with 30 mg/kg 3TC once daily beginning the day before inoculation until implant collection. No reductions occurred in mice treated with 500 µg isotype control mAb under the same regimen as PG16 and PG9. (B) Mean HIV RNA was reduced to ≤102.5 copies per 106 implant cells in mice treated i.p. with 1.5–150 µg PG16 three times per week beginning the day before inoculation and continuing until implant collection at 14 days. (C) Statistically significant reductions in HIV RNA occurred in mice starting with a dose of 0.5 µg PG16 three times per week beginning the day before inoculation, and HIV RNA was undetectable in 2 of 5 mice treated with a single administration of 5 µg PG16 the day before inoculation. The columns represent means, and the open circles represent individual mice. **P<0.01 compared to untreated HIV-infected mice by the Mann-Whitney U test. The dotted line indicates the HIV RNA detection limit. (101.5 copies per 106 implant cells).